Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastrointest Surg. Aug 27, 2025; 17(8): 106499
Published online Aug 27, 2025. doi: 10.4240/wjgs.v17.i8.106499
Table 1 Comparison of general data of two groups of patients, n (%)
Factors
Study group (n = 37)
Control group (n = 37)
P value
Age50.67 ± 11.4951.16 ± 10.580.869
Body weight (kg)76.19 ± 8.4875.02 ± 8.160.546
BMI (kg/m2)26.13 ± 4.3827.05 ± 5.150.369
Disease course (weeks)3.13 ± 0.573.23 ± 0.520.653
Platelet (× 109/L)228.17 ± 50.21220.48 ± 57.070.682
Erythrocyte (× 109/L)4.69 ± 0.674.75 ± 0.590.637
Leukocyte (× 109/L)8.12 ± 1.197.91 ± 1.320.474
Sex0.661
Male27 (72.97)31 (77.50)
Female10 (27.03)9 (22.50)
Smoking0.768
Yes25 (67.57)29 (72.50)
No12 (32.43)11 (27.50)
Alcohol consumption0.488
Yes29 (78.38)30 (75.00)
No8 (21.62)10 (25.00)
Exercise habit0.717
Yes4 (10.81)3 (7.50)
No33 (89.19)37 (92.50)
Ethnicity0.506
Han35 (94.59)37 (92.50)
Minority2 (5.41)3 (7.50)
Pathological stage0.612
Stage I-II17 (45.95)22 (55.00)
Stage III-IV20 (54.05)18 (45.00)
Lymphatic metastasis0.527
Yes12 (32.43)11 (27.50)
No25 (67.57)29 (72.50)
Intestinal obstruction degree0.848
Complete24 (64.86)27 (67.50)
Incomplete13 (35.14)13 (32.50)
Primary tumor0.879
Colon cancer15 (40.54)18 (45.00)
Rectal cancer22 (59.46)22 (55.00)
Histological type0.974
Adenocarcinoma14 (37.84)15 (37.50)
Mucinous carcinoma13 (35.14)14 (35.00)
Undifferentiated carcinoma10 (27.02)9 (22.50)
Differentiation degree0.875
Well-differentiated20 (54.05)19 (51.35)
Moderately differentiated8 (21.62)8 (21.62)
Poorly differentiated9 (24.33)10 (27.03)
Table 2 Comparison of 12 months follow-up results, n (%)
Group
Control group (n = 37)
Study group (n = 37)
P value
Tumor recurrence rate5 (13.51)1 (2.70)0.097
Overall survival rate34 (91.89)36 (97.30)0.317